Join

or

Existing user? Login

Biosimilar pharmaceuticals

Few differences observed in safety information for biosimilars and related originators

A cross-sectional analysis of the safety concerns of biosimilars, compared with their originator products, shows very similar results.

Biosimilars have been available in the European Union for more than ten years, but their uptake in routine care across the region is highly variable.

A cross-sectional analysis was conducted on publicly available information on biosimilars and their originators, filed for regulatory purposes at European Medicines Agency level. A total of 19 biosimilars and 6 originators were included.

Overall, 142 safety concerns were retrieved, corresponding to 55 general safety concerns. Of these, 22(40%) were classified as highly clinically relevant, with 21(38%) as medium and 12(22%) as low clinical relevance.

For all substances, except infliximab, no, or only one, difference was found in the safety concerns reported for biosimilars and their originators. For infliximab, a single difference was considered a highly clinically relevant safety issue.

Direct comparison between biosimilars and related originators through formal post-marketing studies remains important to evaluate specific safety and effectiveness issues, the researchers concluded in the British Journal of Clinical Pharmacology (online, 22 November 2017)[1].

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204187

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50
  • BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50
  • Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00
  • Essentials of Economic Evaluation in Healthcare

    An introduction to economic evaluation specific to healthcare, for those with little or no knowledge of economics. Covers cost effectiveness, cost utility and cost benefit analysis.

    £33.00
  • Information Technology for Pharmacists

    £22.00

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Supplementary images

  • Identical vials

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

farm-pump-ua.com/

our company antibioticlistinfo.com

www.adulttorrent.org